MTN-042 Operational Guidance #04: Initiation of Cohort 2 Accrual

This operational guidance document provides instruction to sites regarding initiation of Cohort 2 accrual.

The MTN-042 Interim Review Panel reviewed safety and primary outcome data from MTN-042 Cohort 1 in June 2021. The IRP noted no safety concerns and recommended that the study proceed with enrollment of the next gestational age cohort as planned. A summary that includes these recommendations from the IRP has been issued with this Operational Guidance document and should be submitted to IRB/EC(s) and Drug Regulatory Agencies that are overseeing the conduct of MTN-042.

Cohort 2 will enroll 150 women in the gestational age range of 30 0/7 weeks – 35 6/7 weeks, and their infants once born. Rather than having site-specific accrual targets, all sites will work cooperatively to reach the overall accrual goals. Per protocol, accrual of Cohort 2 should be complete within 4-5 months of the date of the first Cohort 2 enrollment at the first site.

Once all items on the site’s MTN-042 Cohort 2 Readiness Checklist have been completed and a signed checklist is issued by FHI 360, the site may initiate recruitment of participants for Cohort 2. Note that prescreening activities as outlined in site SOPs may take place prior to issuing this notice, but no Cohort 2 screening and enrollment visits should take place prior to receiving this signed checklist.

Participants screening for Cohort 2 should be informed verbally of the Cohort 1 IRP safety review and their recommendations before enrollment. Furthermore, maternal participants in Cohort 1 should be informed of the outcome of the Cohort 1 IRP safety review. This can be completed at the next routinely scheduled infant visit (i.e., the Month 6 or Month 12 visit) or over the phone, per the discretion and preference of the site.

Below are suggested counseling messages to provide verbally to participants. Should sites want to develop supplemental written materials to facilitate provision of this information, please notify FHI 360. As to not delay availability of this information, sites should proceed to counsel participants verbally while waiting on IRB/EC approvals of any written materials. Sites should document provision of this information to participants on visit checklists and/or chart notes.

Cohort 1 IRP Safety Review - Counseling Messages

- The MTN-042 Interim Review Panel (IRP) reviewed safety and pregnancy outcome data from the first group of women enrolled in the study (Cohort 1) in June 2021. This was a planned review that is part of the study design.
- The IRP is an external group of subject matter experts from North America and Sub-Saharan Africa. There are 7 members from the fields of obstetrics/gynecology, pediatrics, public health, ethics, and statistics.
- The IRP noted no safety concerns and recommended that the study move forward as planned to enroll the next group of women (Cohort 2). Women in Cohort 2 will be slightly earlier in their pregnancy at enrollment, between 30-35 weeks.
- Additional details about Cohort 1 and the safety data reviewed are as follows:
  - Women in Cohort 1 were between 36-37 weeks pregnant when they enrolled. The review included safety data through the time of their delivery.
  - Cohort 1 enrolled 150 participants across 4 study sites:
    - Kampala, Uganda: 44 participants
    - Johannesburg, South Africa: 42 participants
    - Chitungwiza, Zimbabwe: 37 participants
Blantyre, Malawi: 27 participants

- A total of 101 participants were randomized to the dapivirine vaginal ring and 49 to oral PrEP (Truvada). Women used the study products they were assigned until delivery.
- Pregnancy outcome data was available from 148 of 150 women enrolled in Cohort 1.
  - Most women had live births (147/148 or 99%). There was one stillbirth.
  - There were 3 preterm births (i.e., delivery before 37 weeks).
  - The frequency of stillbirth and preterm birth was lower than the rate generally observed in the communities where the study is being conducted.
- Overall, pregnancy complications were rare and lower than the rate generally observed in the study communities.
- There were 4 maternal and 14 infant safety events that were serious, including one infant death following delivery. All serious maternal and infant events were considered not related to the study products by investigators.
- There was one moderate case of nausea in a maternal participant considered related to oral PrEP by the investigator.
- The rate of observed congenital anomalies is similar to what is generally observed in the study communities.

In summary, in this first cohort of pregnant women using the dapivirine vaginal ring or oral PrEP (Truvada) late in pregnancy, adverse pregnancy outcomes, pregnancy complications, and adverse infant outcomes were uncommon and were similar to or lower than rates observed in the communities where the study is being conducted.

What questions or concerns do you have?

All Operational Guidance documents must be printed and filed with study essential documents.

Approval Signature(s)/Date(s):

DocuSigned by:

Ashley Mayo

Signer Name: Ashley Mayo
Signing Reason: I approve this document
Signing Time: 23-Jun-2021 12:27 EDT

Ashley Mayo, Sr. Clinical Research Manager, FHI 360
**Certificate Of Completion**

Envelope Id: 3270514A98944B699880C7C74ABC9DBB

Subject: Please DocuSign: MTN042 Operational Guidance 04-v1.0_23JUN2021.docx

CF02:
Project Code/Charge Code: 100123.801.001

Source Envelope:
Document Pages: 2
Certificate Pages: 5
AutoNav: Enabled
Enveloped Stamping: Enabled
Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Envelope Originator:
Ashley Mayo
359 Blackwell Street, Suite 200
Durham, NC 27701-2477
AMayo@fhi360.org
IP Address: 73.36.165.195

**Record Tracking**

Status: Original
Holder: Ashley Mayo
AMayo@fhi360.org
Location: DocuSign

**Signer Events**

<table>
<thead>
<tr>
<th>Signature</th>
<th>Timestamp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashley Mayo</td>
<td>6/23/2021 12:26:44 PM</td>
</tr>
<tr>
<td><a href="mailto:amayo@fhi360.org">amayo@fhi360.org</a></td>
<td>6/23/2021 12:27:31 PM</td>
</tr>
<tr>
<td>Family Health International Inc - Part 11</td>
<td>6/23/2021 12:28:00 PM</td>
</tr>
</tbody>
</table>

Security Level: Email, Account Authentication (Required)

Signature Adoption: Pre-selected Style
Signature ID:
E35C3483-DC33-4F63-9685-A017DB5F043C
Using IP Address: 73.36.165.195

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

**Electronic Record and Signature Disclosure:**
Accepted: 11/6/2019 1:40:28 PM
ID: 65b116f5-2a06-4080-8a0e-fe9e97084303

**In Person Signer Events**

**Editor Delivery Events**

**Agent Delivery Events**

**Intermediary Delivery Events**

**Certified Delivery Events**

**Carbon Copy Events**

**Witness Events**

**Notary Events**

**Envelope Summary Events**

<table>
<thead>
<tr>
<th>Status</th>
<th>Timestamp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hashed/Encrypted</td>
<td>6/23/2021 12:26:44 PM</td>
</tr>
<tr>
<td>Security Checked</td>
<td>6/23/2021 12:28:00 PM</td>
</tr>
<tr>
<td>Security Checked</td>
<td>6/23/2021 12:28:00 PM</td>
</tr>
<tr>
<td>Payment Events</td>
<td>Status</td>
</tr>
<tr>
<td>----------------</td>
<td>--------</td>
</tr>
<tr>
<td>Electronic Record and Signature Disclosure</td>
<td></td>
</tr>
</tbody>
</table>
ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Family Health International Inc - Part 11 (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a $0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically
Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Family Health International Inc - Part 11:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:
To contact us by email send messages to: nzimmerman@fhi360.org

To advise Family Health International Inc - Part 11 of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at nzimmerman@fhi360.org and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Family Health International Inc - Part 11

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to nzimmerman@fhi360.org and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Family Health International Inc - Part 11

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:
i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to nzimmerman@fhi360.org and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process.

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: https://support.docusign.com/guides/signer-guide-signing-system-requirements.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Family Health International Inc - Part 11 as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Family Health International Inc - Part 11 during the course of your relationship with Family Health International Inc - Part 11.